Aralez Pharmaceuticals — Jefferies Healthcare Conference 2016
17 slides from Aralez Pharmaceuticals's conference presentation, Jun 9, 2016
Slide 1: Forward-looking statements
This presentation includes certain statements that constitute “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, statements regarding the successful execution of our commercialization strategy with respect to Fib
Slide 2: The Aralez Investment Thesis
The Aralez Investment Thesis Aralez is an emerging global specialty pharmaceutical company designed to: Maximize the value of a broadened portfolio, growing revenue base and geographic footprint across North America and Europe Build on our anchor positions in cardiovascular disease and pain manageme
Slide 3: Aralez: The Base Business
Aralez: The Base Business Canadian Revenue Base Key contributors include Cambia®, Durela® & Soriatane® Ongoing Royalty Stream Receive a 10% royalty on U.S. and ex-US sales of VIMOVO®; Patented until 2031 Receive 20% of CPPIB receipts on TREXIMET® starting in April 2018 Evolving Cardiovascular Portfo
Slide 4: FIBRICOR: Commercial Objectives
FIBRICOR: Commercial Objectives Drive broader utilization among targets and educate HCPs on how to Rx Capitalize on copay program Leverage affordability and flexibility of both the brand and AG 105 mg script is not substitutable Objective: Increase market share from the fenofibrate/fenofibric acid m
Slide 5: FIBRICOR Performance – Early Indicators
FIBRICOR Performance – Early Indicators Source: Symphony Health Phast Fibricor Franchise Weekly NRx Began Promotion with 25 Reps 50% lift in NRX volume
Slide 6: YOSPRALA Positioning & Regulatory Status
YOSPRALA Positioning & Regulatory Status YOSPRALA has a coordinated delivery mechanism composed of an enteric-coated aspirin (325 mg or 81mg core), surrounded by immediate-release omeprazole (40 mg) for the secondary prevention of heart attack and stroke for patients at risk for an aspirin-induced u
Slide 7: YOSPRALA: Phase 3 Clinical Data
PA32540-301 and PA32540-302 ITT Population; PA32540 (n=524), EC ASA (n=525). PA32540-treated subjects had significantly fewer UGI symptoms. Overall occurrence of major adverse cardiovascular events (MACE) was low, with no significant differences between treatments in types or incidence of MACE. P <
Slide 8: Challenges of Compliance with Aspirin Therapy
Adjusted HR HR, hazard ratio within the first 6 months 2. Derogar M et al. Clin Gastroenterol Hepatol. 2013;11(1):38-42. Odds Ratio 3.1* P=0.0001 * OR=3.14 (1.75–5.61). 1. Biondi-Zoccai GG et al. Eur Heart J. 2006;27(22):2667-2674. Nonadherence to Aspirin Therapy is Associated with a 3-FOLD Higher R
Slide 9: Disease Awareness and Education Initiatives
Disease Awareness and Education Initiatives There may be a hole in his aspirin therapy New guidelines published in the Journal of The American College of Cardiology provide opportunity for other advocacy groups to refresh their recommendations Aspirin is assumed in EVERY instance of Dual Antiplatele
Slide 10: YOSPRALA: U.S. Market Share Opportunity
18.3M 70% take aspirin2 6.3M take aspirin plus PPI/H23 26.2M secondary prevention patients1 Mozaffarian D, Heart Disease and Stroke Statistics – 2015 Update. Fang J, Use of Low-dose Aspirin as Secondary Prevention of Atherosclerotic CVD among US adults (From the National Health Interview Survey, 201
Slide 11: YOSPRALA: Commercial Readiness and Strategy
YOSPRALA: Commercial Readiness and Strategy Deployed a 25 person high quality sales force that has started promotion of Fibricor and is building relationships with key cardiologists Upon FDA approval, plan to launch YOSPRALA with ~110 sales professionals (including 25 previously hired for Fibricor),
Slide 12: Aralez: Global Regulatory Update
Aralez: Global Regulatory Update U.S.: YOSPRALA (PA32540/PA8140) NDA filing 505b(2) application; NDA recently resubmitted FDA PDUFA goal date of September 14, 2016; targeting launch in 4Q 2016 EUROPE: PA10040 MAA filing (YOSPRALA) US NDA package will form core of submission CMC, bioequivalence and p
Slide 13: Aralez: A Compelling Platform for Growth
Aralez: A Compelling Platform for Growth Canadian domiciled with an Irish presence Aralez Pharmaceuticals Trading DAC holds IP & plans to execute acquisition and operating strategy Corporate structure offers competitive advantage Strong balance sheet and financial position As of 1Q16, cash of approx
Slide 14: Business Development: Value Creation Strategy
Aligned, value creating and transformative M&A Primary Focus on the U.S. and Canada and selective global expansion Opportunistic Approach to Other Specialty Therapeutic Areas Business Development: Value Creation Strategy Near-term EBITDA Accretive & Revenue Generating Products Approved Products in C
Slide 15: Aralez - Our Near Term Priorities
Aralez - Our Near Term Priorities Continue financially disciplined build up of organization Commercial execution of the recent promotional launch of Fibricor YOSPRALA PDUFA goal date of September 14, 2016; target launch in 4Q 2016, pending FDA approval Plan to submit YOSPRALA in Europe in 4Q 2016 an
Slide 16: Corporate Overview & Strategic Vision
“Corporate Overview & Strategic Vision” Jefferies Healthcare Conference June 9, 2016
Slide 17: Aralez Pharmaceuticals – Jefferies Healthcare Conference
/rale2 Pharmaceuticals Breathing New Life Into Pharmaceuticals™ Jefferies Healthcare Conference “Corporate Overview & Strategic Vision” June 9, 2016
Aralez Pharmaceuticals — Jefferies Healthcare Conference 2016 on 6ix